S

AN FRANCISCO — A global pharma company is teaming up with federal research labs and academics in an ambitious effort to slash the time spent screening potential cancer drugs before they make it into the clinic for testing.

The new consortium — dubbed Accelerating Therapeutics for Opportunities in Medicine, or ATOM —  unveiled its plans on Friday, after a nearly two years of planning. Its goal: To cut the preclinical development time from six years to one.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy